Figure 3 | Gene Therapy

Figure 3

From: A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent

Figure 3

Specificity of miR inhibitors. (a) Sequence of miR-17 inhibitor and specific mutations to test function. The numbers indicate the mutated ribonucleotide (bold and in caps) and the AUCA sequence in the middle of the inhibitor sequence eliminates a perfect match.27 The seed sequence of the mature miR-17-5p is in bold as is the antisense sequence to the seed sequence in PMIS-miR-17. (b) Ribonucleotide mutation effects on miR inhibitor efficiency. Normalized Rluc to Fluc ratio of miR reporter vector without miR-17 binding site was set as 100%. The PMIS-miR-17 inhibitor mutants were co-transfected with miR reporter vector containing a miR-17 binding site into HEK 293FT cells. Rluc and Fluc activity was measured 48 h after transfection. T-test was performed against the sample, marked by arrow. *P<0.05 and **P<0.01.

Back to article page